Dysbiosis of gut microbiota in COVID-19 is associated with intestinal DNA phage dynamics of lysogenic and lytic infection

Bacteriophages infect and replicate with bacteria and archaea and are closely associated with intestinal bacteria. The symbiotic relationship between gut microbiota and bacteriophages is of interest, but it is challenging to study their dynamics in the human body over time. SARS-CoV-2 infection has...

Full description

Saved in:
Bibliographic Details
Published inMicrobiology spectrum Vol. 13; no. 1; p. e0099824
Main Authors Ishizaka, Aya, Tamura, Azumi, Koga, Michiko, Mizutani, Taketoshi, Yamayoshi, Seiya, Iwatsuki-Horimoto, Kiyoko, Yasuhara, Atsuhiro, Yamamoto, Shinya, Nagai, Hiroyuki, Adachi, Eisuke, Suzuki, Yutaka, Kawaoka, Yoshihiro, Yotsuyanagi, Hiroshi
Format Journal Article
LanguageEnglish
Published United States American Society for Microbiology 07.01.2025
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Bacteriophages infect and replicate with bacteria and archaea and are closely associated with intestinal bacteria. The symbiotic relationship between gut microbiota and bacteriophages is of interest, but it is challenging to study their dynamics in the human body over time. SARS-CoV-2 infection has been reported to alter the gut microbiota, which is involved in gut immune regulation and pathophysiology, although changes in the intestinal phages of patients with SARS-CoV-2 and their dynamic relationship with the gut microbiota remain unclear. SARS-CoV-2 infection, which follows a transient pathological course from disease onset to cure, may provide a reliable model to investigate these interactions in the gut environment. Therefore, this study aimed to elucidate the correlation between gut microbiota and intestinal DNA virome dynamics in COVID-19 pathogenesis. This study found that the dysbiosis observed in SARS-CoV-2 infection involves a growth strategy that depends on the phage or bacterial dominance.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Y.K. has received unrelated funding support from Daiichi Sankyo Pharmaceutical, Toya-ma Chemical, Tauns Laboratories, Inc., Shionogi & Co. LTD, Otsuka Pharmaceutical, KM Biologics, Kyoritsu Seiyaku, Shinya Corporation, and Fuji Rebio, and is a co-founder of FluGen.
Aya Ishizaka and Azumi Tamura contributed equally to this article. Author order was determined on the basis of alphabetical order.
ISSN:2165-0497
2165-0497
DOI:10.1128/spectrum.00998-24